Suchergebnisse - "Palandri, Francesca"

PubPharm (38)

1

MANIFEST : Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Mascarenhas, J. | Kremyanskaya, M. | Patriarca, A. | +21

2

Management of polycythemia vera : A survey of treatment patterns in Italy

enthalten in: European journal of haematology | 2023

von Palumbo, G. | Breccia, M. | Baratè, C. | +7

3

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis : interim analysis from an Italian, prospective cohort study (ROMEI)

enthalten in: Leukemia & lymphoma | 2022

von Guglielmelli, P. | Palandri, F. | Selleri, C. | +14

4

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study) : a multicentre, randomised phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Barbui, T. | Vannucchi, A. | De Stefano, V. | +34

ErratumIn: Lancet Haematol. 2021 Mar;8(3):e170. - PMID 33515489

5

Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease

enthalten in: Journal of experimental & clinical cancer research : CR | 2021

von Forte, D. | Barone, M. | Morsiani, C. | +16

6

Is there a gender effect in polycythemia vera?

enthalten in: Annals of hematology | 2021

von Palandri, F. | Mora, B. | Gangat, N. | +1

7

Ruxolitinib discontinuation syndrome : incidence, risk factors, and management in 251 patients with myelofibrosis

enthalten in: Blood cancer journal | 2021

von Palandri, F. | Palumbo, G. | Elli, E. | +33

8

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

enthalten in: Nature | 2020

von Jayavelu, A. | Schnöder, T. | Perner, F. | +29

9

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib : Real-world data

enthalten in: Hematological oncology | 2020

von Palandri, F. | Breccia, M. | Tiribelli, M. | +30

10

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

enthalten in: British journal of haematology | 2020

von Al-Ali, H. | Griesshammer, M. | Foltz, L. | +19